Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability

Title of the cohort

Acronym for cohort

FINGER

Name of Principal Investigator

Title	Docent, Ass Professor
First name	Miia
Last name	Kivipelto

Address of institution where award is held

Institution	Univeristy of Eastern Finland
Street Address	Yliopistonranta 1 B
City	Kuopio
Postcode	70211

Country

Finland

Website

www.thl.fi/finger

Contact email

[email protected]

Funding source

Academy of Finland
Kuopio Univeristy Hospital
Univeristy of Eastern Finland
Alzheimer Association USA

1. The cohort includes, or expects to include, incidence of the following conditions

Alzheimer’s disease and other dementias

When studies on the above condition(s) are expected to become possible

2011 – 2015

2a. Stated aim of the cohort

Multimodal intervention study in subjects with increased risk for Alzheimer’s disease and with slight memory impairment.

2b. Features distinguishing this cohort from other population cohorts

Multimodal 2-year intervention study in subjects with increased risk for Alzheimer’s disease and with slight memory impairment.

3a. i) Number of publications that involve use of cohort to date

3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

3b. Publication list/link to where data or publications are accessible (if available)

3c. Information (i.e. research findings) expected to be gained from the population cohort

4a. Study criteria: age range of participants at recruitment

Age in years from:	60-75 years
To (‘until death’ if applicable):

4b. Study criteria: inclusion criteria

High dementia risk score (Kivipelto et al 2006) and objective evidenced memory /
cognitive impairment

4c. Study criteria: exclusion criteria

Dementia, any major disease preventing participation in the intervention

5. Size of the cohort (i.e. number of participants enrolled)

1,000 – 5,000 participants

6a. Measures used to characterise participants

Demographic, health, cognition, functional capacity, cardiovascular fitness parameters…

6b. Additional measures for participants with a clinical disorder

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

7. Study design

Other (please specify)
Randomized intervention study

8. Cases matched by

9a. Does the study include a specialised subset of control participants

9b. If yes, description of specialised subset of control participants

10a. i) Data collection start date

01-09-2009

10a. ii) Data collection end date

31-12-2013

10a iii) Data collection for this study is

Data collection ongoing

10b. Plans to continue the cohort study beyond the current projected end date

Yes – intend to apply for funding

11. Data collected

Only through the study
Through links to medical records
Through links to other records or registers (such as dental records, police records etc). Please specify
###VALUE###

12. System in place to enable re-contact with patients for future studies

Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database

	Yes/No	% available
Data summarised in database
Database is web-based	Yes
Database on spreadsheet
Database is on paper	No
Other (specify)

Language used:

Finnish /English

13b. Format and availability of data held as individual records

	Yes/No	% available
Data held as individual records	Yes
Data is web-based	Yes
Data held on computer based records	Yes
Data held on cards
Other (specify)

Language used:

Finnish /English

14a. Are data available to other groups

Yes

14b. Access policy/mechanisms for access if data are available to other groups

Access through collaboration with PI only

15. Data sharing policy specified as a condition of use

No requirement to make data publicly available

16a. Are tissues/samples/DNA available to other groups

Yes

16b. i) Description of available tissues/samples/DNA

Living donors:blood
Living donors: blood derivatives
Living donors: DNA

16b. ii) Form available tissues/samples/DNA are supplied in

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

Yes

17. Is information on biological characteristics available to other groups